Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 15/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782766 | 1.00 | CCR5 (0.45) | CCR5GPBAR1TMEM97 | |
| SCHEMBL3786187 | 0.86 | CCR5 (0.45) | CCR5TMEM97 | |
| SCHEMBL3786192 | 0.86 | CCR5 (0.45) | CCR5TMEM97 | |
| SCHEMBL3776626 | 0.81 | CCR5 (0.43) | CCR5TMEM97 | |
| SCHEMBL3776628 | 0.81 | CCR5 (0.43) | CCR5TMEM97 | |
| SCHEMBL13434086 | 0.79 | CCR5 (0.59) | CCR5 | |
| SCHEMBL19540968 | 0.78 | TMEM97 (0.56) | TMEM97 | |
| SCHEMBL1591952 | 0.78 | CTSD (0.42) | TMEM97 | |
| SCHEMBL1591950 | 0.78 | CTSD (0.42) | TMEM97 | |
| SCHEMBL8008172 | 0.77 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254876-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | AstraZeneca AB (SE) | 2010-12-01 | — | — | EP | claimed |
| WO-2009105026-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20090215841-A1 | D2 Receptor Ligand-078 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | claimed |
| EP-2254876-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | AstraZeneca AB (SE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009105026-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215841-A1 | D2 Receptor Ligand-078 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215841-A1 | D2 Receptor Ligand-078 | TACR2, TACR1, GPR174 | CCR5 167/4885GPBAR1 106/4885TMEM97 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.